s
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
31-07-2024, 17:14
BOSTON, July 31, 2024 /PRNewswire/ — Recently, Shanghai Medicilon Inc. (“Medicilon”) and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”) reached a strategic collaboration agreement. The cooperative efforts will focus on preclinical evaluation of new drug modalities, particularly ADCs, small nucleic acids, and CGT (cell and gene therapy) drugs. The goal of this partnership is to advance the innovation […] L'articolo Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs proviene da La Ragione.
CONTINUA A LEGGERE
10
0
0
Guarda anche
La Ragione
01:43
Champions dolceamara per l’Atalanta, 0-0 contro l’Arsenal
La Ragione
Ieri, 23:43
G7 cultura, Giuli accoglie delegazioni a Napoli
La Ragione
Ieri, 22:43
La Russa “Non sono complottista, centrodestra non è accerchiato”
La Ragione
Ieri, 20:43
Sinner ambassador di Milano-Cortina, Malagò “Ha entusiasmo e umiltà”
La Ragione
Ieri, 20:38
Torna Striscia la notizia con la velina e il velino. Tutte le novità della 37esima edizione
La Ragione
Ieri, 20:04